Objective: Many premature infants at risk for bronchopulmonary dysplasia experience episodes of surfactant dysfunction with reduced surfactant protein B (SP-B). In this study, we investigated the safety and responses to booster doses of surfactant.
Introduction
Infants born prematurely often have respiratory failure because of structurally immature lungs, deficiency of pulmonary surfactant, primitive respiratory drive and susceptibility to infection. The need for assisted ventilation and supplemental oxygen in these infants contributes to a form of chronic lung injury initially described by Northway et al. 1 as bronchopulmonary dysplasia (BPD). In recent years, a new form of BPD has occurred in extremely low birth weight infants, which is characterized by impaired alveolar development, with excess tone and reactivity of pulmonary arterial and airway smooth muscle, 2, 3 and a requirement for ventilatory support and/or supplemental oxygen at 36 weeks of postmenstrual age. 4 The typical infant who develops BPD has respiratory distress syndrome that improved with the administration of surfactant after birth. Despite requiring only minimal ventilatory and/or supplemental oxygen support by 3 to 5 days of life, more than 50% of these infants enter a phase of 'evolving BPD,' characterized by a progressive increase in need for supplemental oxygen and ventilatory support, increasingly abnormal chest radiographs and episodes of respiratory deterioration often associated with infection.
The etiology of BPD is clearly multifactorial and involves derangements in multiple aspects of lung function (for example, surfactant production), repair from injury (for example, elastin deposition) and growth and development (for example, alveologenesis). These derangements of normal development are likely mediated, in part, by chronic inflammation that develops in the immature lung exposed to repetitive ventilator stretch with oxygen-enriched gas, often complicated by infection. 5 Infants subsequently developing BPD demonstrate early evidence of chronic pulmonary inflammation, characterized by persistently elevated lung lavage fluid concentrations of selected cytokines (tumor necrosis factor-a, matrix metalloproteinase-2/9/12, interleukin (IL)-1b, IL-6, IL-8, complement component C5-derived anaphylatoxin, leukotriene B 4 , platelet-activating factor, soluble interstitial cell adhesion molecule and transforming growth factor (TGF)-b) and b-chemokines (macrophage inflammatory protein1a, monocyte chemotactic protein-1, monocyte chemotactic protein-2, monocyte chemotactic protein-3 and regulated upon activation, normal T cell expressed and secreted (RANTES)). 6, 7 Pulmonary surfactant is a mixture of lipids and proteins that provides the surface-active alveolar film required for normal lung function and survival. Two of the surfactant-associated proteins, surfactant protein (SP)-B and SP-C, are intimately associated with surfactant lipids and are crucial for surfactant film formation and function in the lung. Reduction of SP-B content to p25% of normal in transgenic mice was associated with reversible inflammation, surfactant dysfunction and respiratory failure, and excess SP-B content preserved pulmonary compliance after exposure of animals to endotoxin. [8] [9] [10] [11] SP-B is also required for proper packaging of surfactant in lamellar bodies within type II respiratory epithelial cells. 12 Inherited deficiency of SP-B in term infants causes respiratory failure and eventual death secondary to inactive surfactant. 13, 14 Most extremely low birth weight infants have a developmental deficiency of surfactant at birth, and numerous clinical trials have established the safety and efficacy of surfactant treatment of premature infants immediately after delivery, 15, 16 with decreased mortality and incidence of air leak syndromes.
Alterations in surfactant function and/or SP concentrations have been reported in patients with acute respiratory distress syndrome, 17 pneumonia, 18 viral bronchiolitis, 19 adult chronic lung disorders 20 and pneumocystis infections. 21 We previously found that 75% of chronically ventilated premature infants had at least one surfactant sample with abnormal function in vitro; in this group of infants, surfactant dysfunction was transient, usually lasting 1 to 2 weeks, highly correlated with low concentrations of SP-B/C and associated with clinically evident respiratory deterioration. 22 Based on these various observations in infants and animal models, we proposed that episodes of surfactant dysfunction contribute to the evolution of BPD by increasing the requirement for ventilatory support with further lung injury.
To date, there are limited data evaluating late surfactant therapy for premature infants who require continuing ventilatory support beyond 1 week of life. Pandit et al. 23 found that FiO 2 decreased significantly at 24 to 72 h after a single dose of surfactant to 10 premature infants. Bissinger et al. 24 also demonstrated a transient improvement in oxygenation of premature infants >7 days after treatment with 2 doses of surfactant. More recently, Katz and Klein, 25 in a retrospective cohort study of 25 premature infants, found that late surfactant treatment was well tolerated and that 70% of those treated had a short-term improvement in respiratory status. A recent multicenter pilot study administered lucinactant (Surfaxin, Discovery Labs, Warrington, PA, USA) to 136 intubated infants on days 3 to 10 of life and reported a trend toward improved survival without BPD (42% lucinactant versus 34% placebo). 26 In this study, we hypothesized that late booster doses of surfactant to ventilated premature infants would be well tolerated, improve respiratory status and increase endogenous surfactant function. Herein, we describe findings of a pilot trial with unblinded booster surfactant treatment in 87 ventilated infants. We examined short-term safety of surfactant dosing and effects on respiratory status, cytokine profile, surfactant composition and surfactant function in vitro.
Methods

Study population
The Booster Pilot Trial was performed at nine centers between November 2004 and November 2007. Institutional Review Board approval for this trial was obtained at each study center, and the parents of all participants provided written, informed consent. Infants of 500 to 1250 g birth weight were enrolled if they were intubated and required ventilatory support between 7 and 10 days of age. Infants were excluded if they were intubated solely for apnea, or if they had serious congenital malformations, active air leak or pulmonary hemorrhage, bilateral grade IV intracranial hemorrhages, or a life expectancy less than 7 days from study enrollment, as determined by the attending physician. Infants were treated with doses of Infasurf exogenous surfactant according to one of 2 dosing protocols: initially infants received up to 2 doses of surfactant, administered at a 7-day interval (11/04 to 08/06). Subsequently, the dosing protocol was changed to up to 3 doses of surfactant at 3-to 4-day intervals (11/06 to 11/07). Infants were redosed with surfactant if they remained intubated and mechanically ventilated during the study period, and felt to be clinically stable as per the attending physician. Infasurf was instilled as per the manufacturer's instructions for treatment of the newborn infant. Clinical data were collected including ventilatory settings from which the respiratory severity score (RSS) was calculated (FiO 2 Â mean airway pressure). The infants within this trial were managed with a common ventilatory strategy to maximize end expiratory pressure, to minimize FiO 2 and peak inspiratory pressure, and to maintain a common saturation goal of 85 to 93.
Tracheal aspirate samples
Specimens of tracheal aspirate fluid (TAF) were collected from a sub-population of enrolled infants at appropriate time points: before treatment (day 0) and at 1, 3 and 7 days after receiving Infasurf. The TAF sampling procedure involved instillation of 0.5 ml of saline into the trachea, brief ventilation and suction at the end of the endotracheal tube to recover saline containing lung epithelial lining fluid. This procedure was repeated twice, and the aliquots were combined into one sample. Samples were centrifuged at 500 Â g for 5 min to remove cells and stored at À70 C in the presence of protease inhibitors.
Surfactant isolation and characterization TAF supernatants were subsequently centrifuged (27 000 Â g for 60 min) to isolate the large aggregate surfactant (pellet) and a supernatant fraction. Total protein was measured by the Bradford assay (BioRad Laboratories, Hercules, CA, USA), and total phospholipids (PLs) were assessed by phosphorous assay of extracted PLs. [27] [28] [29] Surface activity was assessed in triplicate in a pulsating bubble surfactometer (Electronectics, Buffalo, NY, USA) 30 using freshly prepared large aggregate surfactant that was resuspended at 1.5 mg PL ml À1 in 10 mM Tris buffer (pH 7.4)/1.5 mM CaCl 2 . Pulsation was at 0.33 Hz for 10 min at 37 1C, varying the bubble radius between 0.4 and 0.88 mm. Using software provided by the manufacturer, we determined the minimum surface tension (STmin). A sample of beractant (Survanta, Abbott Nutrition, Columbus, OH, USA) surfactant was run in each assay as a control and consistently provided a STmin <4 mN m
À1
. SP-B was measured in large aggregate surfactant by immunodot assay as previously described. 31, 32 Briefly, serial dilutions of surfactant samples along with Infasurf as standard were applied to nitrocellulose and exposed to primary and secondary antibody, and chemiluminescence in the presence of enhanced chemiluminescence reagent (Pierce Biotechnology, Rockford, IL, USA) was quantitated in a phosphorimager (Molecular Dynamics, Sunnyvale, CA, USA). SP-B results are expressed as % of PL by weight.
Cytokine assay TAF supernatant samples (n ¼ 55) from 11 infants were assayed in duplicate for IL-1a, IL-1b, IL-6, IL-8, macrophage inflammatory protein-1a, RANTES, tumor necrosis factor-a and TGF-b1 by multiplex assay in the Laboratory of Flow Cytometry at Roswell Park Cancer Institute (Buffalo, NY). This automated procedure determines concentrations of multiple cytokines in a single aliquot of a sample using specific antibodies. Results were expressed as pg ml À1 or pg per mg total protein in the sample. 
Results
A total of 87 infants were enrolled: 44 in the 2-dose protocol and 43 in the 3-dose protocol. For the entire group, mean birth weight and gestational age were 727 g and 25.3 weeks, respectively. Approximately 75% of the infants received antenatal corticosteroids and all received replacement surfactant at birth. The mean age at enrollment was 8.8 days with a median RSS of 2.9. There were no significant differences between study participants in the 2-versus the 3-dose protocol ( Table 1) .
Safety of treatment
We examined clinical events associated with surfactant dosing as well as selected comorbidities of prematurity during and after surfactant treatment. All of the participants received the first surfactant dose, whereas 68 and 81% of infants received the second dose in the 2-and 3-dose protocols, respectively. In all, 74% of the 3-dose participants received the third scheduled dose. Of the total of 184 doses for the 87 infants, there were 13 instances of transient bradycardia (7.1%) and 5 occurrences of plugged endotracheal tube (2.7%). All episodes resolved without the need for significant resuscitation. There were no significant issues with pulmonary interstitial emphysema, pneumothorax or pulmonary hemorrhage around each of the dosing events. There were no other significant changes in comorbidities, including patent ductus arteriosus, intracranial hemorrhage and necrotizing enterocolitis for infants, before versus after surfactant treatment (data not shown).
Change in RSS Figure 1a shows the median RSS values for all surfactant doses before and for 72 h after treatment. Compared with a pretreatment value of 3.51, the RSS was significantly decreased (P<0.0001) at 1 h (3.18), 2 h (3.12) and 24 h (3.29), returning to the pretreatment level at 48 h. The response was similar for initial and subsequent doses of Infasurf (data not shown). 3-dose protocol was less than that of the 2-dose protocol, but the difference was not statistically significant. Survival to discharge was 93.2 and 95.3% for the 2-and 3-dose protocols respectively. Of those surviving to discharge, 19.5% of infants in the 2-dose protocol and 36.6% of infants in the 3-dose protocol were without BPD at 36 weeks of postmenstrual age. However, the trial was not designed nor powered to assess a difference in this outcome.
Surfactant studies
Surfactant samples were available for study on a subset of 30 infants in the trial. The infants had a mean gestational age of 25.4 weeks, mean birth weight of 628 g and a median RSS at study entry of 4.4. We assessed surfactant function in vitro in a pulsating bubble surfactometer and measured SP-B and total protein content of large aggregate surfactant. Table 2 shows values at study entry. Consistent with our earlier observations, 22 most of these intubated infants (76%) had dysfunctional surfactant, as defined by a STmin >5 mN m À1 , and there was a relatively low amount of SP-B (median 0.34% versus normal of B1%).
We assessed surfactant function and composition at 1, 3 and 7 days after treatment (Figure 2) . In this analysis, the pretreatment value (day 0) for each infant was used to calculate change at 1, 3 and 7 days, expressed as % of control, and median values were determined for the skewed data. The STmin of isolated surfactant was significantly lower at 1 day after Infasurf treatment but not at 3 and 7 days after Infasurf treatment as compared with the pretreatment value (Figure 2a) . The content of SP-B was 75% greater at 1 day after dosing, similar to at 3 day after, and significantly lower at 7 day after Infasurf treatment as compared with pretreatment (Figure 2b ). This later decrease likely reflects clearance of SP-B from the instilled Infasurf and reduced production of endogenous SP-B. By contrast, there was no increase in total protein associated with surfactant at 1 day after treatment (Figure 2c ). These findings suggest a transient (>1 day and <3 days) improvement in endogenous surfactant composition and function after treatment.
Analysis of TAF cytokines
To examine possible effects of booster surfactant treatment on pulmonary inflammatory status, we determined concentrations of selected cytokines in TAF obtained both before and after treatment. Assays were performed on available, remaining samples (11 infants) at five time points (pretreatment and 1, 2, 3 and 7 days after a dose of surfactant). In preliminary analyses, we tested for correlations between levels of different cytokines in infants using all 55 values for each cytokine. As shown in Table 3 , correlations were observed between levels of many of the seven proinflammatory cytokines examined, with r-values ranging from 0.93 to 0.42 and P-values all <0.001. By contrast, levels of anti-inflammatory TGF-b1 were not correlated with any of the seven cytokines. This observation of correlated cytokine levels has been confirmed in separate cohorts of infants (not shown): IL-1b versus IL-8 (519 samples from 52 infants, r ¼ 0.69), IL-6 versus IL-1b, IL8 versus IL-1b and IL-6 versus IL-8 for 51 samples from 17 infants (r ¼ 0.73, 0.57 and 0.58, respectively). These findings suggest that the inflammatory response in infant lung involves a coordinated increase in a variety of proinflammatory mediators. We next examined for changes in TAF cytokine concentrations over time after surfactant treatment. There were no statistically significant increases or decreases in any of the eight analytes at 3 and 7 days after treatment (Figure 3 ) or at days 1 and 2 (data not shown) compared with baseline (day 0). Thus, we found no evidence of increased inflammation after surfactant, further supporting the safety of booster doses.
Discussion
Our studies addressed the proposal that transient episodes of dysfunctional surfactant, secondary in large part to decreased content of SP-B, contribute to the pathogenesis of BPD in premature infants. In this pilot trial, we investigated the feasibility, safety and selected effects of administering booster doses of Infasurf to infants at high risk for BPD. This surfactant preparation was chosen because of its relatively high concentration of SP-B. 33 Our results support previous observations that late surfactant instillation has a relatively low incidence of known, acute side effects and also transiently improves respiratory status. [23] [24] [25] [26] New findings are the improved in vitro function and increased SP-B content of Abbreviations: IL, interleukin; MIP, macrophage inflammatory protein; NS, not significant; RANTES, regulated upon activation, normal T cell expressed and secreted; TAF, tracheal aspirate fluid; TGF, transforming growth factor; TNF, tumor necrosis factor. Values shown are correlation coefficients (r) for regression analyses between cytokines with a positive slope and P<0.001. Data from tracheal aspirates of 11 infants at study entry and at 1, 2, 3 and 7 days after treatment (n ¼ 55). Levels of all cytokines except TGF-b1 are correlated with three to six other cytokines. NS ¼ r<0.4 and P>0.001.
endogenous surfactant after a booster dose, with a time course of response similar to that for respiratory status. We also document that booster surfactant does not alter proinflammatory cytokines in lung fluid. We have previously reported an association between the presence of dysfunctional surfactant in ventilated premature infants and respiratory decompensation. 22 There was a trend toward amelioration of the rate of respiratory deterioration of the infants during the second week of life with 3 versus 2 doses of late surfactant, although this difference did not reach significance. Collectively, these results provide rationale for further studies of late surfactant, perhaps with more frequent and/or additional surfactant doses given the loss of improvement in respiratory status and tracheal sample SP-B content by 48 hr after each treatment.
We confirmed in this cohort the frequent occurrence of dysfunctional surfactant (elevated STmin) and low SP-B content in surfactant of ventilated premature infants. 22 Thus, most of the infants in the trial had evidence of abnormal surfactant and were candidates for additional doses of replacement surfactant, despite a median initial RSS value of 2.9. Because reduced recovery of surfactant is not associated with poor function, 22 the acquired abnormality in these infants appears to be reduced amount of SP-B that is required for normal surface properties. This could result from decreased synthesis or processing of proSP-B, perhaps secondary to elevated cytokines such as tumor necrosis factor-a and TGF-b, which downregulates SP-B in vitro. [34] [35] [36] Alternatively, turnover of SP-B could be increased. The transient increase in SP-B content of surfactant after each Infasurf dose (return to baseline by 3 days) is consistent with the reported turnover kinetics observed for endogenous SP-B in stable isotope studies. 37 These observations support the concept that booster surfactant doses should be administered every 2 to 3 days to maintain sufficient SP-B content. This approach increases the alveolar load of surfactant lipid; however, clearance is apparently rapid, as we did not observe increased recovery of surfactant PL in TAF 1 day after a booster dose. Alternatively, and probably preferably, replacement SP-B therapy could be accomplished by instilling surfactant enriched in SP-B on a continuous basis using a nebulized formulation. However, this approach is not currently available.
There is considerable evidence linking early postnatal elevations in proinflammatory cytokines in TAF with development of BPD (reviewed in Ryan et al., 2008) . 7 We assayed cytokines to evaluate whether booster surfactant might be an inflammatory stimulus, and we found no evidence of increased cytokine concentrations. Of interest, we found strong correlations between concentrations of various proinflammatory cytokines in TAF. Importantly, there were no correlations between proinflammatory cytokines and TGF-b, which is anti-inflammatory and profibrotic. It is possible therefore that the cytokine milieu in lung fluid represents a coordinated inflammatory response to lung injury. This concept is supported by a similar report of cytokines in cord plasma, indicating a coordinated proinflammatory mediator response to injury in the infant. 38 Of a practical note, measurement of a single cytokine, such as tumor necrosis factor-a or IL-1b, under these conditions may be sufficient to evaluate the inflammatory status in lung air spaces. It will be of interest to test this relationship between cytokine concentrations earlier in the postnatal course.
There are limitations to this study. The trial was not blinded, and accordingly, all laboratory analyses compared values after treatment with the pretreatment value for each infant. Additionally, we do not have a control group for clinical safety data, and thus it is possible that the rate of side effects attributed to booster surfactant instillation is somewhat lower than we report. We studied tracheal aspirates that are obtained by suctioning at the end of the endotracheal tube and thus represent airway surfactant. However, previous results indicate that airway surfactant closely resembles that obtained by deep suctioning. [39] [40] [41] Finally, we obtained TAF samples at limited time points, and therefore cannot fully define the kinetics of responses to surfactant treatment.
Currently, there are limited therapeutic approaches for prevention of BPD in high-risk infants. Administration of vitamin A has a significant but modest impact on incidence and is routinely used in some centers. 42 Postnatal dexamethasone provides both short-and long-term pulmonary benefit in some infants; however, this therapy is associated with adverse neurodevelopmental outcome and therefore is not recommended for routine use. 43 In two trials, administration of inhaled nitric oxide improved pulmonary outcome, and some centers currently use nitric oxide in high-risk infants beginning at days 7 to 14 of postnatal age. 44, 45 Because BPD is a multifactorial disease, involving lung immaturity, surfactant deficiency and/or dysfunction, injury with inflammation and abnormal growth, it is unlikely that any single therapy will have a marked impact on disease incidence. Additionally, there is convincing evidence from twin studies for a genetic component in BPD, 46 which likely affects responses of individual infants to specific therapies. These considerations suggest that future strategies for effective prevention of BPD will involve a combination of therapies targeting different components of the pathogenesis. Our current and previous findings support booster surfactant treatment in conjunction with other therapies as one approach to be evaluated. We recently began enrollment in a randomized controlled trial of additional and more frequent doses of late surfactant in infants receiving inhaled nitric oxide (the TOLSURF trial) to evaluate safety and efficacy of this combined therapy.
